Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Kenneth F. Grossmann"'
Autor:
Siwen Hu-Lieskovan, Kenneth F. Grossmann, Sarah Colonna, John R. Hyngstrom, Justin C. Moser, Shiven B. Patel, Jian Ying, Danli Chen
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7637-7643 (2019)
Cancer Medicine
Cancer Medicine
Background The optimal treatment sequence for patients with advanced BRAF V600 mutant melanoma is unknown. BRAF/MEK inhibition (BRAF/MEKi), single agent anti‐PD‐1 (aPD‐1) antibodies and combination immune checkpoint inhibition with nivolumab an
Autor:
Gary C. Doolittle, Thach Giao Truong, Bryan A. Faller, James Moon, Robert M. Conry, Janice M. Mehnert, Adil Daud, Amy K. Harker-Murray, Dennis F. Moore, Michael J. Messino, Alain Algazi, Roger S. Lo, Antoni Ribas, Christopher D. Lao, Kenneth F. Grossmann, Joseph I. Clark, Kari Kendra, Rangaswamy Govindarajan, Luke Dreisbach, Megan Othus
Publikováno v:
Nat Med
Nature medicine, vol 26, iss 10
Nature medicine, vol 26, iss 10
Preclinical modeling suggests that intermittent BRAF inhibitor therapy may delay acquired resistance when blocking oncogenic BRAFV600 in melanoma1,2. We conducted S1320, a randomized, open-label, phase 2 clinical trial (NCT02196181) evaluating whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3928f445a7b302bd631e90a1c4fdbe25
https://europepmc.org/articles/PMC8063889/
https://europepmc.org/articles/PMC8063889/
Autor:
Ammar Sukari, Susan S. Pandya, Kenneth M. Attie, Dawn Wilson, Jade Sun, Kenneth F. Grossmann, Roger B. Cohen, Elizabeta C. Popa, Jared Weiss, Lori J. Wirth, Matthew L. Sherman, Chad E. Glasser, Xiaosha Zhang, Marshall R. Posner, Athanassios Argiris, Nabil F. Saba, Antonio Jimeno
Publikováno v:
Cancer. 122:3641-3649
BACKGROUND Patients with platinum-refractory, recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) have limited options. Activin receptor-like kinase 1 (ALK1) is a type I receptor of the transforming growth factor β superf
Autor:
Melissa Wright, R. Dirk Noyes, William T. Sause, Ying J. Hitchcock, Douglas Grossman, Glen M. Bowen, Kenneth F. Grossmann, Amanda Truong, Hung T. Khong, John R. Hyngstrom, Tawnya L. Bowles, Alyssa Winters, John Snyder, Robert H.I. Andtbacka
Publikováno v:
Melanoma research. 30(2)
Surgical management of external ear melanoma presents unique technical challenges based on the unique anatomy and reconstruction concerns. Surgical technique, including preservation of cartilage, is variable and impact on recurrence is unclear. Our g
Autor:
Ahmad A. Tarhini, Michael B. Atkins, Christopher J. Anker, John M. Kirkwood, Gita Suneja, Kenneth F. Grossmann
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 95:632-646
BRAF kinase gene V600 point mutations drive approximately 40% to 50% of all melanomas, and BRAF inhibitors (BRAFi) have been found to significantly improve survival outcomes. Although radiation therapy (RT) provides effective symptom palliation, ther
Autor:
Kenneth F. Grossmann, David A. Wada, Douglas Grossman, Kenneth M. Boucher, Ying J. Hitchcock, Glen M. Bowen, Sheri L. Holmen, Hung Khong, Morgan Ward, John R. Hyngstrom, Gita Suneja, Adam L. Cohen, Laura J. Gardner, Martin McMahon, Robert H.I. Andtbacka, Marcus M. Monroe, Carolyn Ross, Tawnya L. Bowles
Melanoma metastasis to the brain is associated with a poor prognosis. We sought to determine patient demographics and primary tumor factors associated with the development of brain metastasis (BM) and survival. We also investigated whether the BM det
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c88ec5e683bb601afbdc7b7a58e2ab8
https://europepmc.org/articles/PMC5583702/
https://europepmc.org/articles/PMC5583702/
Autor:
David F. McDermott, Jean-Jacques Grob, Michael A. Postow, Jedd D. Wolchok, Dirk Schadendorf, Kenneth F. Grossmann, Rafia Bhore, Caroline Robert, James Larkin, F. Stephen Hodi, Piotr Rutkowski, Jason Chesney, Dana Walker, Rene Gonzalez, C. Lance Cowey, Christopher D. Lao, Vanna Chiarion-Sileni
Purpose Approximately 40% of patients with advanced melanoma who received nivolumab combined with ipilimumab in clinical trials discontinued treatment because of adverse events (AEs). We conducted a retrospective analysis to assess the efficacy and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7853a4d1d4f3e1184d56532a4a87db48
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85034023934
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85034023934
Autor:
David R. Minor, Jeffrey K. Giguere, Matthew H. Taylor, Marc S. Ernstoff, April K.S. Salama, David F. McDermott, Kenneth F. Grossmann, Caroline Robert, Michael A. Postow, Jason Chesney, Christine Horak, Paul Gagnier, Anna C. Pavlick, F. Stephen Hodi, Gerald P. Linette, Patrick A. Ott, Sanjiv S. Agarwala, Nicolas Meyer, Joel Jiang, Montaser Shaheen, Jedd D. Wolchok
Publikováno v:
The Lancet. Oncology. 17(11)
Summary Background Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of
Autor:
Eleni Tsiroyanni, Merrick I. Ross, Yan Wang, Robert H. Pierce, Lu Gan, Melinda L. Yushak, Kenneth F. Grossmann, Robert H.I. Andtbacka, Katie Niland, Mohammed M. Milhem, Sudha Parasuraman, Jean S. Campbell, Kam Sprott
Publikováno v:
Cancer Research. 78:613-613
Background: The CXCR4/CXCL12 pathway plays a central role in the trafficking of key immune cells in the tumor microenvironment (TME). X4P-001 is an oral, selective, allosteric CXCR4 inhibitor. We hypothesize that the disruption of CXCR4/CXCL12 signal
Autor:
James C. Moon, Michael Wu, Kenneth F. Grossmann, Antoni Ribas, Siwen Hu-Lieskovan, Jeffrey A. Sosman, Danae Campos, Christopher W. Ryan
Publikováno v:
Journal of Clinical Oncology. 36:TPS9603-TPS9603
TPS9603Background: A significant number of patients do not respond to PD-1/L1 blockade because there are no pre-existing tumor antigen-specific T-cells in their tumors ready to attack the cancer. W...